JP2024515885A5 - - Google Patents

Info

Publication number
JP2024515885A5
JP2024515885A5 JP2023566921A JP2023566921A JP2024515885A5 JP 2024515885 A5 JP2024515885 A5 JP 2024515885A5 JP 2023566921 A JP2023566921 A JP 2023566921A JP 2023566921 A JP2023566921 A JP 2023566921A JP 2024515885 A5 JP2024515885 A5 JP 2024515885A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
compound
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026898 external-priority patent/WO2022232487A1/en
Publication of JP2024515885A publication Critical patent/JP2024515885A/ja
Publication of JP2024515885A5 publication Critical patent/JP2024515885A5/ja
Pending legal-status Critical Current

Links

JP2023566921A 2021-04-30 2022-04-29 パーキンソン病を処置及びモニタリングするための方法 Pending JP2024515885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182207P 2021-04-30 2021-04-30
US63/182,207 2021-04-30
PCT/US2022/026898 WO2022232487A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Publications (2)

Publication Number Publication Date
JP2024515885A JP2024515885A (ja) 2024-04-10
JP2024515885A5 true JP2024515885A5 (cg-RX-API-DMAC10.html) 2025-05-09

Family

ID=83847331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566921A Pending JP2024515885A (ja) 2021-04-30 2022-04-29 パーキンソン病を処置及びモニタリングするための方法

Country Status (9)

Country Link
US (1) US20240207266A1 (cg-RX-API-DMAC10.html)
EP (1) EP4329763A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024515885A (cg-RX-API-DMAC10.html)
CN (1) CN117769422A (cg-RX-API-DMAC10.html)
AU (1) AU2022267325A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217230A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023012851A (cg-RX-API-DMAC10.html)
TW (1) TW202308635A (cg-RX-API-DMAC10.html)
WO (1) WO2022232487A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051214A1 (zh) * 2023-09-07 2025-03-13 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN121226329A (zh) * 2024-06-28 2025-12-30 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物
CN119119035B (zh) * 2024-08-30 2025-11-04 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
CN118878521B (zh) * 2024-09-26 2025-02-14 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164323A1 (en) * 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos

Similar Documents

Publication Publication Date Title
US6231889B1 (en) Unit dosage forms for the treatment of herpes simplex
TWI280136B (en) Composition containing dipeptide of histidine and alanine for reducing uric acid
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法
JP2017066153A (ja) L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
US20240299364A1 (en) Magnesium biotinate compositions and methods of use
EP3380094B1 (en) Butyrate salts for use in inflammatory diseases
US20220370467A1 (en) Using of a ppar-delta agonist in the treatment of kidney disease
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
JP2006501224A (ja) アルギニンケイ酸塩イノシトール複合体およびその使用
RU2004131214A (ru) Способы лечения когнитивных расстройств
CN106511366A (zh) 治疗缺血性脑中风的药物及其制备方法与用途
JP2006524190A5 (cg-RX-API-DMAC10.html)
US20060062849A1 (en) Oral formulation of creatine derivatives and method of manufacturing same
EP4719402A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
AU2016402338A1 (en) Combinational compositions and methods of use thereof
JP2024084670A5 (cg-RX-API-DMAC10.html)
EP0306377A1 (fr) Nouvelles compositions d'éléments minéraux et/ou oligoéléments et leur procédé de préparation
WO2003057198A1 (fr) Compositions pharmaceutiques a liberation modifiee
US20170296499A1 (en) Combinational compositions and methods of use thereof
EP3283066B1 (en) 4-phenylbutyric acid derivatives
US20060062853A1 (en) Treating neuromuscular disorders with an oral formulation of creatine derivatives
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
JP2025535162A (ja) βアドレナリン作動及びムスカリン拮抗組成物並びに使用方法
AU2269495A (en) Use of isosorbide-5-mononitrate
JP2024541770A5 (cg-RX-API-DMAC10.html)